Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.01 per share
-
Shares outstanding
-
46,239,275
-
Total 13F shares
-
9,149,141
-
Share change
-
+422,586
-
Total reported value
-
$394,154,000
-
Put/Call ratio
-
0%
-
Price per share
-
$43.06
-
Number of holders
-
62
-
Value change
-
+$17,909,350
-
Number of buys
-
31
-
Number of sells
-
33
Institutional Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) as of Q4 2018
As of 31 Dec 2018,
UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) was held by
62 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
9,149,141 shares.
The largest 10 holders included
MENORA MIVTACHIM HOLDINGS LTD., Consonance Capital Management LP, WELLINGTON MANAGEMENT GROUP LLP, Wildcat Capital Management, LLC, FMR LLC, HIGHLINE CAPITAL MANAGEMENT, L.P., MEITAV DASH INVESTMENTS LTD, Clal Insurance Enterprises Holdings Ltd, CITADEL ADVISORS LLC, and BlackRock Inc..
This page lists
62
institutional shareholders reporting positions in this security
for the Q4 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.